Immuneering (IMRX)Chief Business Officer bought ~$25K
Harold Eugene Brakewood, Chief Business Officer at Immuneering, bought ~$25K of Immuneering shares.
- ~$25K
- Approx. value · 5,250 sh @ $4.76
- 11K
- Holds after · shares reported
- Traded
- Jan 16, 2026
- Filed
- Jan 21, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Jan 12, 2026InsiderDirector purchased ~$87K of IMRX shares in the open market
- Jan 13, 2026InsiderOfficer purchased ~$11K of IMRX shares in the open market
- Jan 15, 2026Insider · 2 peopleInsiders: 2 purchases (~$112K)
- Jan 16, 2026 · this disclosureInsider · 5 insiders in a week, 4th time since 2021Officer purchased ~$25K of IMRX shares in the open market
What came next
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Immuneering
OQRO holds no insider, Congress, fund or contract record for Immuneering dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IMRX page.
Other recent filings by Harold Eugene Brakewood, Chief Business Officer
The full history of Harold Eugene Brakewood, Chief Business Officer is on the profile page.
How this filing works
Other disclosures at Immuneering
- SEC Form 4Jun 24, 2026
- SEC Form 4Jun 16, 2026
- SEC Form 4Jan 20, 2026
- SEC Form 4Jan 16, 2026
- SEC Form 4Jan 15, 2026
- SEC Form 4Jan 14, 2026
Everything OQRO holds on this company is on its IMRX page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO Pro is a paid subscription. You see the price before you pay
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data